EBR Systems, Inc. reported a net loss of $48.8 million for the fiscal year ending December 31, 2025, an increase of 19.5% compared to a net loss of $40.8 million in 2024. The company's revenue for the year was $1.6 million, attributed to the commercial launch of its WiSE CRT System, which received FDA approval in April 2025. This marked a significant milestone for EBR, as it began generating revenue from its only product, the leadless cardiac pacing system designed to treat heart rhythm conditions without traditional leads. The company had previously reported no revenue in 2024, highlighting the impact of the product's market entry.
In terms of operational metrics, EBR Systems trained 33 physicians to implant the WiSE CRT System and signed 21 purchase agreements with hospitals during 2025. The company reported commercial implants at eleven hospitals in the U.S., indicating a focused strategy on high-volume medical facilities. However, the company continues to face challenges, including a substantial accumulated deficit of $402.2 million and ongoing negative cash flows from operations, which totaled $53.2 million for the year. These financial indicators raise concerns about the company's ability to sustain operations without additional capital.
Strategically, EBR Systems has made significant investments in expanding its sales and marketing capabilities, with plans to increase its U.S. sales force and enhance international marketing efforts. The company aims to drive adoption of the WiSE CRT System and expand its customer base in both existing and new markets. Additionally, EBR is committed to conducting a post-approval study to further validate the safety and effectiveness of the WiSE CRT System, which is a requirement of its FDA approval.
As of December 31, 2025, EBR Systems had approximately $54.2 million in cash, cash equivalents, and marketable securities, down from $66 million in the previous year. The company has raised capital through various financing activities, including a $33.5 million institutional placement and a $12.8 million rights offering in 2025. However, the company expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for additional capital to support its operations and growth initiatives. The outlook for EBR Systems remains uncertain, as it navigates the complexities of commercialization and seeks to establish a foothold in the competitive medical device market.
About EBR Systems, Inc.
EBR Systems, Inc. develops leadless cardiac pacing technology, including the WiSE CRT System, for heart rhythm correction. Its innovative implantable devices deliver ultrasound-based left-ventricle pacing without leads, targeting patients with heart failure unresponsive to conventional therapies. The company focuses on regulatory approval, clinical trials, and commercialization in the U.S. and international markets, emphasizing safety, efficacy, and intellectual property protection in the medical device sector.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.